首页> 美国卫生研究院文献>Experimental and Therapeutic Medicine >Effects of indigo naturalis on colonic mucosal injuries and inflammation in rats with dextran sodium sulphate-induced ulcerative colitis
【2h】

Effects of indigo naturalis on colonic mucosal injuries and inflammation in rats with dextran sodium sulphate-induced ulcerative colitis

机译:靛蓝对葡聚糖硫酸钠诱导的溃疡性结肠炎大鼠结肠黏膜损伤和炎症的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The effects of indigo naturalis (IN), which is a traditional Chinese herbal formulation, have been clinically demonstrated in treating refractory ulcerative colitis (UC). The present study aimed to verify the effects and mechanisms of IN in experimental UC rats. A total of 48 male Sprague-Dawley rats were randomly divided into six groups: Chow, model, high-dose IN, medium-dose IN, low-dose IN and mesalazine (a bowel-specific aminosalicylate drug) groups. The models were administered 3.5% dextran sodium sulphate solution for 7 days. The treatment groups were administered IN or mesalazine and then sacrificed and sampled on day 8. Disease activity index (DAI), histological damage score (HDS) and myeloperoxidase (MPO) activity were used to evaluate the severity of UC. Colon and serum cytokines were detected using liquid-phase chip technology and the expression of occludin protein in colonic mucosa was assessed by immunohistochemistry and western blot analysis. The results indicated that the oral administration of IN may reduce DAI, HDS and MPO activity. IN also reduced the expression of inflammatory cytokines and increased the expression of colonic mucosal repair-related cytokines and occludin protein. These results highlight the potential of IN as a therapeutic agent for treating UC through its action of inflammation control and colonic mucosal damage repair.
机译:天然靛蓝(IN)是一种传统的中草药配方,已在治疗难治性溃疡性结肠炎(UC)中得到了临床证明。本研究旨在验证IN在实验性UC大鼠中的作用和机制。将总共​​48只雄性Sprague-Dawley大鼠随机分为六组:松鼠,模型,高剂量IN,中剂量IN,低剂量IN和美沙拉嗪(一种肠特异性氨基水杨酸盐​​药物)组。给模型施用3.5%的葡聚糖硫酸钠溶液7天。给治疗组注射IN或美沙拉嗪,然后在第8天处死并取样。使用疾病活动指数(DAI),组织损伤评分(HDS)和髓过氧化物酶(MPO)活性评估UC的严重程度。使用液相芯片技术检测结肠和血清中的细胞因子,并通过免疫组织化学和蛋白质印迹分析评估occludin蛋白在结肠粘膜中的表达。结果表明,口服IN可能会降低DAI,HDS和MPO活性。 IN还降低了炎性细胞因子的表达,并增加了结肠粘膜修复相关细胞因子和occludin蛋白的表达。这些结果突出了IN作为通过其炎症控制和结肠粘膜损伤修复作用来治疗UC的治疗剂的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号